Protocol of the phase 3 study of the drug for the treatment of COVID-19
2 November 2020
CPD has prepared a protocol for a phase 3 study of a promising broad-spectrum drug used in the treatment of patients with coronavirus infection (COVID-19) of moderate and severe forms as part of standard therapy.
After the approval of the Ministry of Health of the Russian Federation, CPD will proceed directly to conduct this study with the participation of 330 patients and more than 18 clinical centers.